Abstract： AIM To evaluate the effect of octreotide combined withomeprazole on gastrointestinal hormones and intestinal mucosal barrier function in patients with acute pancreatitis (AP). METHODS One hundred and twenty-four patients with AP treated from July 2016 to June 2017 at People's Hospital of Guyuan were divided into an observation group and a control group. The control group was given omeprazole alone, and the observation group was given octreotide combined with omeprazole. Two weeks after treatment, the clinical efficacy, clinical symptoms, gastrointestinal hormones, intestinal mucosal barrier function, and adverse reactions were compared between the two groups.RESULTS The effective rate was significantly higher in the observation group than in the control group [90.32％ (59/62) vs 80.65％ (50/62), χ2 = 6.143, P< 0.05). Time to disappearance of fever, abdominal pain, nausea and vomiting, abdominal distension, abdominal tenderness, and other clinical symptoms and signs was significantly shorter in the observation group than in the control group (2.12 d ± 0.55 d vs 4.56 d ± 0.72 d, 1.75 d ± 0.42 d vs 4.34 d ± 0.70 d, 2.23 d ± 0.56 d vs 4.65 d ± 0.74 d, 2.54 d ± 0.60 d vs 4.12 d ± 0.76 d, 2.12 d ± 0.53 d vs 4.24 d ± 0.75 d; t = 21.205, 24.982, 20.533, 20.185, 18.177, P< 0.01). Serum MTL was significantly higher and serum GAS and VIP were significantly lower in the observation group than in the control group (318.36 pg/mL ± 30.24 pg/mL vs 256.45 pg/m L ± 34.23 pg/m L, 14.12 μmol/L ± 16.25 μmol/L vs 130.24 μmol/L ± 16.45 μmol/L, 58.12 pg/mL ± 7.25 pg/mL vs 64.36 pg/mL ± 8.12 pg/mL; t = 10.673, 5.489, 4.514, P< 0.05 or P< 0.01). Serum ET, DLA, DAO, and AMY were significantly lower in the observation group than in the control group (53.12 ng/L ± 7.25 ng/Lvs 64.20 ng/L ± 7.36 ng/L, 4.45 μg/L ± 0.78 μg/L vs 6.42 μg/L ± 0.86 μg/L, 6.47 U/L ± 1.12 U/L vs 9.10 U/L ± 1.26 U/L, 124.36 U/L ± 24.35 U/L vs 160.21 U/L ± 26.54 U/L; t = 8.445, 13.360, 12.284, 7.818, P< 0.05 or P< 0.01). The rate of adverse reactions was significantly lower in the observation group than in the control group [8.06％ (5/62) vs 24.19％ (15/62), χ2 = 5.962, P< 0.05].CONCLUSION Octreotide combined with omeprazole can improve clinical symptoms and clinical curative effect and reduce adverse reactions in patients with AP, which may be related to regulating gastrointestinal hormones and improving intestinal mucosal barrier function.